-
1001
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Published 2024-07-01“…This review will discuss the challenges and opportunities associated with translating HIF inhibition into clinical practice, including ongoing clinical trials and future directions in the development of HIF-based cancer treatments.…”
Get full text
Article -
1002
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review
Published 2025-01-01“…We also review the representation of age, racial, and ethnic groups in key CAR-T clinical trials. We focus on B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin’s lymphoma, and multiple myeloma.…”
Get full text
Article -
1003
A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
Published 2019-05-01“…This review provides information on the association of MM and Btk in conjunction with the treatment using ibrutinib. To date, clinical trials of ibrutinib as therapeutic alternative for MM have produced promising results, particularly as combination therapy with other agents such as dexamethasone and carfilzomib. …”
Get full text
Article -
1004
Repurposing radiosensitising medicines for radiotherapy: an overview
Published 2024-07-01“…Using a literature-based approach, we identified 42 radiosensitising drugs with varied non-cancer indications and mechanisms of action, that have entered or completed clinical trials in combination with RT or with chemoradiotherapy. …”
Get full text
Article -
1005
TNF-α as a Therapeutic Target in Acute Pancreatitis — Lessons from Experimental Models
Published 2007-01-01“…Different specific and nonspecific inhibitors have been developed with promising results in animal models, but, on the other hand, no clinical trials have been designed so far. Difficulties in clinical applications may be multifactorial; experimental models are not fully reliable and reproduce at least some aspects of human disease, timing of intervention should be related to changes in TNF-α serum levels, and inclusion criteria should be accurately selected to better define the population most likely to benefit.…”
Get full text
Article -
1006
Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
Published 2017-01-01“…Further research and clinical trials are needed to study patients with uncommon BRAF mutations and the potential therapeutic benefit of immunotherapy.…”
Get full text
Article -
1007
Onychomycosis: Potential of Nail Lacquers in Transungual Delivery of Antifungals
Published 2016-01-01“…Penetration efficiency was assessed by several researchers across the human nail plate to investigate the potentiality of nail lacquer based formulations. Various clinical trials have also been conducted in order to evaluate the safety and efficacy of nail lacquers in delivering antifungal agents. …”
Get full text
Article -
1008
Leadless Pacing: Current Status and Ongoing Developments
Published 2025-01-01“…In order to clarify the role(s) of leadless pacing, this narrative review was undertaken by searching MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and review articles, as well as other clinically relevant reports and studies. …”
Get full text
Article -
1009
The Physiology, Pharmacology and Therapeutic Manipulation of the Internal Anal Sphincter
Published 2002-01-01“…The initial results with this medical approach to anorectal disease have often been disappointing, failing to match the results achievable with surgery, and many of these drugs have a high rate of side effects in the short term. However, clinical trials have yet to establish the optimum doses, dose intervals and routes of administration for many of these therapies. …”
Get full text
Article -
1010
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Published 2025-01-01“…Several therapeutic antibodies that counter the immunosuppressive tumor microenvironment have demonstrated efficacy in clinical trials, leading to FDA approvals for advanced HCC treatment. …”
Get full text
Article -
1011
Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros
Published 2017-01-01“…In nearly all asymptomatic PWD, however, the results of screening will generally not change medical therapy, since aggressive preventive measures, such as control of blood pressure and lipids, would have been already indicated, and above all, invasive revascularization procedures (either with percutaneous coronary intervention or coronary artery bypass grafting) have not been shown in randomized clinical trials to confer any benefit on morbidity and mortality. …”
Get full text
Article -
1012
In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayi
Published 2010-01-01“…Two of the derivatives, 17-N-allyl-17-demethoxygeldanamycin (17-AAG) and 17-N-(2-dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG), are currently in human clinical trials as anticancer drugs. Using concentrations considered safe peak plasma concentrations for these two derivatives, all four derivatives were active against both parasites. …”
Get full text
Article -
1013
Multiple Culprit Coronary Artery Thrombosis in a Patient with Coronary Ectasia
Published 2018-01-01“…Although routine aspiration thrombectomy in STEMI was not proven to be beneficial in randomized clinical trials, it was of great value in this case. We also discuss the relation between coronary ectasia, chronic inflammatory status, and increased platelet activity which may have caused plaque disruption in another already vulnerable vessel.…”
Get full text
Article -
1014
Assessing Health-Related Quality of Life in Asthma
Published 1997-01-01“…The questionnaires chosen for review have good measurement properties and validity and can be used in both clinical trials and clinical practice to assess the impact of asthma on a patient’s life. …”
Get full text
Article -
1015
Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies
Published 2018-01-01“…Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. …”
Get full text
Article -
1016
Analysis of the Modified Rankin Scale in Randomised Controlled Trials of Acute Ischaemic Stroke: A Systematic Review
Published 2016-01-01“…Historically, most acute stroke clinical trials were neutral statistically, with trials typically dichotomising ordinal scales, such as the modified Rankin Scale. …”
Get full text
Article -
1017
Phosphate Frustration: Treatment Options to Complement Current Therapies
Published 2022-01-01“…We present treatment options to complement current therapies including tenapanor, a novel sodium/hydrogen exchanger isoform 3 inhibitor that blocks the dominant paracellular phosphate absorption pathway and has been shown to reduce phosphate levels in several clinical trials.…”
Get full text
Article -
1018
Outcome differences in acute vs. acute on chronic heart failure and cardiogenic shock
Published 2020-06-01“…Abstract Aims Despite advances in coronary reperfusion and percutaneous mechanical circulatory support, mortality among patients presenting with cardiogenic shock (CS) remains unacceptably high. Clinical trials and risk stratification tools have largely focused on acute CS, particularly secondary to acute coronary syndrome. …”
Get full text
Article -
1019
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women
Published 2025-01-01“…., those listed in PubMed/Medline, Embase, Scopus, the Cochrane Database, International Clinical Trials Registry, and ClinicalTrials.gov). We examined published randomized controlled trials (RCTs) and prospective studies. …”
Get full text
Article -
1020
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
Published 2025-03-01“…This trial was registered at ClinicalTrials.gov (NCT04396457) and the Japan Registry of Clinical Trials (jRCTs041200012).…”
Get full text
Article